Oryzon Genomics S.A. (ORYZF) Research

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions. The company's clinical pipeline features two key compounds. Iadademstat (ORY-1001), a selective LSD1 inhibitor, is currently undergoing Phase II trials for various oncological indications. Similarly, vafidemstat (ORY-2001), another LSD1 inhibitor specifically designed for CNS applications, is also in Phase II for the treatment of neurological and psychiatric illnesses. Furthermore, ORY-3001, an LSD1 inhibitor, is progressing through preclinical development with the aim of addressing non-cancerous diseases. Established in 2000, Oryzon Genomics is headquartered in Cornellà de Llobregat, Spain.

Market snapshot

Symbol
ORYZF
Price
$3.65
Day change
0.00%
Market cap
$247.6M
P/E ratio
-111.63x
52-week range
3.03-4.375
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month

Peer companies

  • China Evergrande New Energy Vehicle Group Limited (EVGRF)
  • Genfit S.A. (GNFTF)
  • Hansa Biopharma AB (publ) (HNSBF)
  • JW (Cayman) Therapeutics Co. Ltd (JWCTF)
  • NervGen Pharma Corp. (NGENF)
  • hVIVO plc (OPORF)
  • Orpea S.A. (ORPEF)
  • Silence Therapeutics plc (SLNCF)

Open Oryzon Genomics S.A. (ORYZF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.